Oral naltrexone 50 mg/d and acamprosate should be first-line pharmacotherapies for alcohol use disorder, according to a systematic review and meta-analysis of randomized clinical trials
“Xylazine pharmacology, animal and human clinical effects, and what is known to date about care of patients experiencing acute overdose, xylazine–fentanyl withdrawal, and xylazine-associated wounds”
Clinical evidence supports effectiveness of cannabis-based medicines in people with multiple sclerosis, chronic pain, and inflammatory bowel disease, and in palliative medicine, according to a
Buprenorphine use declined among privately insured American adults with opioid use disorder (OUD) as out-of-pocket (OOP) costs increased, a study shows. “Policies addressing patient-level hurdles
Use and misuse of alcohol are reviewed with a focus on pharmacotherapeutic management. “Alcohol is regularly consumed throughout most of the world, including by nearly
Rather than disease-specific care, integrated care is needed for older veterans involved in the criminal legal system (CLS) because of a high risk of co-occurring mental
In a Norwegian study, patients with substance-induced psychosis were 6 times more likely to transition to schizophrenia spectrum disorder than to bipolar disorder. “Gender, age,
FDA should consider differences in how tobacco products are marketed to and used by people of different biological sexes and gender identities as it develops
In a trial of 608 U.K. participants with chronic pain from nonmalignant causes, a group-based intervention significantly reduced opioid use but not affecting perceived pain
Following events such as nonfatal drug overdoses, use of medications for treating opioid use disorder (OUD) differed based on race and ethnic background, according to
